ESMO ADVANCED COURSE PROGRAMME

ADC DEVELOPMENT, THERAPEUTIC APPLICATIONS AND RESEARCH: BREAST, GYNAECOLOGICAL AND GI CANCERS

Zurich, Switzerland 4-5 October 2024

CHAIRS Giuseppe Curigliano, Italy

Elizabeth Smyth, United Kingdom

SPEAKERS Nicoletta Colombo, Italy

Elisa Fontana, United Kingdom Maria Fernanda Mosele, France

Barbara Pistilli, France Giancarlo Pruneri, Italy Andrea Sartore Bianchi, Italy

LEARNING OBJECTIVES

- To provide insights on ADCs drug development
- To explain mechanism of action of the most common ADCs used in clinical practice
- To highlight the integration of ADCs in current clinical practice guidelines across pathologies
- To provide guidance on management of toxicities of ADCs

Friday, 4 October 2024

09:00-09:10	Welcome and introduction	
10'	Welcome and Learning Objectives Introduction Giuseppe Curigliano, IT and Elizabeth Smyth, UK	
09:10-10:40	Session 1 – ADC Development and pharmacodynamics	
20'	ADC development: What are the considerations in early phase trials Maria Fernanda Mosele, FR	
20'	Mechanisms of action and resistance: ADC internalization and cleavage and mechanisms of resistance Barbara Pistilli, FR	
20'	Toxicity: Prediction, identification and treatment Elisa Fontana, UK	
30'	Discussion	
10:40-11:10	Coffee break	

11:10-12:10	Session 2 – Target assessment and rational for combinations	
20'	Considerations from pathology —biomarker selection, on target off tumour expression off target toxicities Giancarlo Pruneri, IT	
20'	How to develop rational combinations and sequencing Giuseppe Curigliano, IT	
20'	Discussion	
12:10-13:10	Lunch	
13:10-15:10	Session 3 – Next generation ADCs	
20'	Developments in ADC constructs including bispecific ADCs Elizabeth Smyth, UK	
20'	Cytokine conjugates Andrea Sartore Bianchi, IT	
20'	Discussion	
20'	Peptide based conjugates Elisa Fontana, UK	
20'	Therapeutic index and rational for ADCs sequencing Barbara Pistilli, FR	
20'	Discussion	
19:30	Networking dinner	

Saturday, 5 October 2024

09:00-12:30 Workshop sessions

Three parallel workshop sessions with 20 delegates in each group (delegates will attend all 3 sessions on a rotational basis)

15' Introduction based on clinical cases presented by speakers

40' Discussion

5' Break

Workshop 1 ADC trials in breast cancer

Giuseppe Curigliano, IT

Workshop 2 ACD trials in GI cancers

Elizabeth Smyth, UK

Workshop 3 ADC trials in gynecological cancers

Nicoletta Colombo, IT

11:00-11:30	Coffee break
11:30-12:30	Workshops continuation
12:30-13:00	Feedback on the workshops from each group
13:00-13:15	Synthesis and wrap-up Giuseppe Curigliano, IT and Elizabeth Smyth, UK
13:15-14:15	Lunch